Pemphigus vulgaris
Pemphigus vulgaris Market

Pemphigus Vulgaris (PV) is a rare, severe autoimmune and intraepithelial disease characterized by flaccid blisters and erosions of the skin and mucous membrane. It is histologically marked by acantholysis and is mediated by circulating desmoglein-reactive autoantibodies directed against keratinocyte cell surfaces.


For the treatment of Pemphigus Vulgaris, the majority of the therapies focus on enhancing the symptoms associated with pemphigus by the reduction of serum autoantibodies, either directly or via generalized immune suppression. The most common medication include corticosteroids (prednisolone), anti-CD20 monoclonal antibodies (rituximab and ofatumumab), corticosteroid-sparing agents (azathioprine, mycophenolate mofetil, etc.), and cyclophosphamide. 


Pemphigus Vulgaris Epidemiological Segmentation 

The Epidemiological Segmentation of Pemphigus Vulgaris in 7MM from 2017 to 2030 is segmented as:- 

  • Total Diagnosed Prevalent Cases of Pemphigus Vulgaris
  • Gender-specific Diagnosed Prevalent Cases of Pemphigus Vulgaris
  • Age-specific Diagnosed Prevalent Cases of Pemphigus Vulgaris
  • Severity-specific Diagnosed Prevalent Cases of Pemphigus Vulgaris


Pemphigus Vulgaris Epidemiology 

  • The total diagnosed prevalent cases of Pemphigus Vulgaris in 7MM in 2017 was 41,217
  • The diagnosed prevalent cases of Pemphigus Vulgaris in the United States were 13,526 in 2017


Pemphigus Vulgaris Market

  • The market size of Pemphigus Vulgaris in 7MM in 2017 was USD 181.78 million. 
  • The United States accounted for the highest market size of Pemphigus Vulgaris, in comparison to the other major markets. 


Pemphigus Vulgaris Market Drivers

  • Approval of MabThera/Rituxan
  • Increasing awareness
  • Rising prevalence rates
  • Updated diagnostic and treatment guidelines


Pemphigus Vulgaris Market Barriers

  • Difficulties in developing new treatment
  • Lack of disease understanding
  • Disease diversity
  • Limited approved and emerging therapies

 

Pemphigus Vulgaris Emerging Drugs

The emerging drugs of the Pemphigus Vulgaris market are 

  • Rilzabrutinib (PRN1008)
  • Ianalumab (VAY736)
  • Efgartigimod (ARGX-113)
  • TPM203

And many others.  


Pemphigus Vulgaris Key Players

The key players in the Pemphigus Vulgaris market are

  • Principia Biopharma
  • Novartis Pharmaceuticals/MorphoSys
  • Argenx BVBA
  • Topas Therapeutics

And many others.